Thyroid hormone use in clinical practice by Israeli endocrinologists: a THESIS* questionnaire survey
In Israel, LT4 tablets are the treatment of choice for hypothyroidism in most clinical scenarios, including in patients with impaired absorption or with persistent symptoms, for whom a combination therapy with LT4 + LT3 is considered by half of respondents. Other LT4 formulations are not widely available in Israel, thus are infrequently considered compared to other European countries. These data suggest that international guidelines regarding the use of various thyroid hormone formulations in specific clinical scenarios are warranted.
Authors
- Roberto Attanasio (ORCID: https://orcid.org/0000-0002-1417-287X)
- Keren Kaminer
- Chagit Adler Cohen
- Roberto Negro (ORCID: https://orcid.org/0000-0002-4319-5923)
- Enrico Papini (ORCID: https://orcid.org/0000-0003-4790-2733)
- László Hegedüs (ORCID: https://orcid.org/0000-0002-9691-7619)
- Eyal Robenshtok (ORCID: https://orcid.org/0000-0002-6268-4212)
- Liat Sasson (ORCID: https://orcid.org/0009-0005-7175-7742)
- Endre Vezekenyi Nagy (ORCID: https://orcid.org/0000-0002-9286-6471)
- Petros Perros
Institutions
- University of Debrecen (HU)
- Tel Aviv University (IL)
- Rabin Medical Center (IL)
- Odense University Hospital (DK)
- Ospedale Regina Apostolorum (IT)
- Associazione Medici Diabetologi (IT)
- Ospedale Vito Fazzi (IT)
- Newcastle University (GB)
Publication Details
- Journal
- Thyroid Research
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1186/s13044-024-00219-2
- Citations
- 1
- Primary Topic
- Thyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.29